Welcome to our dedicated page for Y-Mabs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-Mabs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (YMAB) generates news that spans commercial oncology performance, clinical development milestones in radioimmunotherapy, and significant corporate transactions. Company announcements consistently describe Y-mAbs as a commercial-stage biopharmaceutical company focused on novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, with its lead commercial asset DANYELZA® (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma.
News coverage for Y-mAbs frequently highlights financial results and segment updates, including quarterly revenue from DANYELZA, ex-U.S. distribution trends, and the allocation of resources between the DANYELZA and Radiopharmaceuticals business units. Earnings releases often discuss cost of goods sold, research and development spending, selling, general, and administrative expenses, and net loss, along with management commentary on operating strategy and capital efficiency.
Another major category of YMAB news involves clinical and R&D developments in the company’s SADA Pretargeted Radioimmunotherapy (PRIT) platform. Press releases describe progress in the GD2-SADA Phase 1 Trial 1001 in GD2-expressing solid tumors, including pharmacokinetic and dosimetry data, and the initiation of the CD38-SADA Phase 1 Trial 1201 in relapsed or refractory non-Hodgkin lymphoma. Y-mAbs also reports on preclinical pharmacokinetic modeling, optimization of radiohaptens such as “Proteus,” and expansion of its radiopharmaceutical pipeline into additional oncology franchises.
Y-mAbs news also covers regulatory and guideline recognition, such as the inclusion of naxitamab-gqgk (DANYELZA) as a Category 2A treatment option in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma. These updates provide context on how DANYELZA is positioned within clinical practice for high-risk neuroblastoma.
A key theme in recent YMAB headlines is corporate transformation and acquisition activity. In August 2025, Y-mAbs announced that SERB Pharmaceuticals, through an affiliate, agreed to acquire the company in an all-cash transaction at $8.60 per share, with an equity value of approximately $412 million, as described in joint press releases and Form 8-K filings. Subsequent news and SEC filings report the commencement and completion of the tender offer, the closing of the merger, and the resulting delisting of Y-mAbs common stock from the Nasdaq Global Select Market.
Investors and observers following YMAB-related news can expect updates on quarterly financial performance, DANYELZA commercial metrics, clinical trial progress for SADA-based programs, radiopharmaceutical R&D strategy, and the implications of the company’s acquisition by an affiliate of SERB Pharmaceuticals. This news flow provides insight into both the historical public-company phase of Y-mAbs and its transition into a privately held subsidiary within a larger specialty pharmaceutical group.
Y-mAbs Therapeutics announced the successful closing of a public offering of 2,804,878 shares at $41.00 per share, raising approximately $115 million in gross proceeds. This offering included the full exercise of underwriters' option for 365,853 additional shares. The shares were offered under a shelf registration statement filed with the SEC and are listed on Nasdaq under the ticker symbol YMAB. Leading investment banks J.P. Morgan, Morgan Stanley, and BofA Securities managed the offering.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) will announce its financial results for the fiscal year ended December 31, 2020, on February 25, 2021, after U.S. market close. A conference call and webcast will follow on February 26, 2021, at 9 a.m. ET, featuring company executives. Y-mAbs is focused on developing antibody-based cancer therapies, boasting one FDA-approved product, DANYELZA® (naxitamab-gqgk), and a pivotal-stage candidate, omburtamab. The press release includes forward-looking statements on business strategies and financial expectations, emphasizing the need for future funding.
Y-mAbs Therapeutics (Nasdaq: YMAB) announced a public offering of 2,439,025 shares at $41.00 each, expected to generate approximately $100 million in gross proceeds. All shares are offered by Y-mAbs, with an additional 365,853 shares available for underwriters to purchase within 30 days. The offering is set to close on February 22, 2021, pending customary conditions. J.P. Morgan, Morgan Stanley, and BofA Securities are the joint book-running managers. Proceeds will support Y-mAbs' advanced product pipeline for cancer therapies, including FDA-approved DANYELZA® and pivotal-stage omburtamab.
Y-mAbs Therapeutics, Inc. (YMAB) has announced a registered underwritten public offering of up to $100 million in shares of its common stock, with a potential additional purchase option of $15 million for the underwriters. The offering will be managed by J.P. Morgan, Morgan Stanley, and BofA Securities, and is subject to market conditions. A shelf registration statement for the shares has been effective since October 15, 2019. Y-mAbs focuses on developing antibody-based therapies for cancer, including its FDA-approved product, DANYELZA®.
Y-mAbs Therapeutics (Nasdaq: YMAB) will present an overview of its business at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 10:00 AM EST. The presentation, led by CEO Dr. Claus Møller, will be accessible via a live webcast. Y-mAbs focuses on developing antibody-based therapies for cancer, featuring an extensive pipeline, including the FDA-approved product DANYELZA® for GD2-expressing tumors and omburtamab, a pivotal-stage candidate targeting B7-H3 tumors.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) has agreed to sell its Priority Review Voucher (PRV) to United Therapeutics Corporation for $105 million. The PRV was awarded alongside the FDA approval of DANYELZA® for treating high-risk neuroblastoma. Y-mAbs will retain 60% of the proceeds, with the remaining 40% going to Memorial Sloan Kettering Cancer Center. This non-dilutive capital is crucial for funding additional research and development. The transaction is subject to customary closing conditions, including anti-trust review.
Y-mAbs Therapeutics (YMAB) has signed a license agreement with SciClone Pharmaceuticals for the co-development and commercialization of its antibodies, DANYELZA® and omburtamab, in Greater China. DANYELZA, FDA approved for treating high-risk neuroblastoma, will now leverage SciClone's expertise in the region. Y-mAbs will receive a $20 million upfront payment, with potential additional milestone payments totaling up to $100 million, plus royalties on sales. The partnership aims to address unmet medical needs in pediatric cancer treatment in China.
Y-mAbs Therapeutics (NASDAQ: YMAB) has signed a distribution agreement with Swixx BioPharma AG to exclusively distribute its antibody DANYELZA® in Eastern Europe, including Russia. DANYELZA, approved by the FDA on Nov 25, 2020, is used for treating relapsed/refractory high-risk neuroblastoma. The agreement covers several countries and allows Swixx to submit registration files on Y-mAbs’ behalf. The company plans to resubmit its Biologics License Application for omburtamab by early 2021. Financial terms of the deal were not disclosed.
Y-mAbs Therapeutics announced a virtual R&D event on December 16, 2020, to present data on DANYELZA, omburtamab, and nivatrotamab. Key opinion leaders discussed advancements in treating high-risk neuroblastoma and osteosarcoma. Notably, DANYELZA showed a 74.3% event-free survival rate at 24 months in first complete remission patients. The company confirmed plans to resubmit omburtamab's BLA to the FDA in early 2021, showcasing supportive survival data. However, initial results for nivatrotamab were less favorable, lacking complete or partial responses.
Y-mAbs Therapeutics (YMAB) announced a compelling clinical update on DANYELZA® (naxitamab-gqgk) for refractory/relapsed high-risk neuroblastoma at the ESMO Immuno-Oncology Virtual Congress 2020. Study 201 showed an overall response rate (ORR) of 68%, with 59% complete responses. The treatment was primarily outpatient, demonstrating a 98% adherence rate and median infusion time of 37 minutes. DANYELZA, recently approved by the FDA, indicates significant potential in addressing unmet medical needs among difficult-to-treat patients.